– This is a big disappointment. Many in this field had probably thought and hoped that the results would be positive even if the effect never was expected to be dramatically large, ” says Kaj Blennow, professor and alzheimerforskare at Gothenburg university.
the Results of the study further presents an extension of the list of unsuccessful attempts to develop drugs that attack the substance beta-amyloid, which, according to the so-called amyloidhypotesen is believed to be the root cause of the dreaded dementia.
In previous studies with the same drug could the company do not show any certain effect, but these studies suggested yet a possible effect in patients with the milder form of the disease. It was Eli Lilly, the current study on patients in early infections,which, moreover, had noted that the participants had the storage of amyloid in the brain.
But the results was, therefore, a setback. Patients randomly assigned to the solanezumab was not given a reduced deceleration of the cognitive ability, as measured by the scale (Adas-cog14, compared with the placebo group.
Although the company said that patients who received solanezumab seemed to be the favored of several effect parameters, but the differences were not large and not statistically significant.
– You can speculate on explanations for the results, that you could possibly have to attack the disease process at an even earlier stage. But all in all, the findings still amyloidhypotesen is losing credibility, says Kaj Blennow.
complete results from the study will be presented at a scientific meeting on 8 december.
Related material
Studies on antibodies against alzheimer’s disease now in the press
the New findings about the alzheimermedicin
Back to the Neurology
No comments:
Post a Comment